Dr. Charles Ryan Discusses IMAAGEN Trial Update for Prostate Cancer
June 23rd 2016
Charles J. Ryan, MD, professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, provides an update to the IMAAGEN trial, which explored the effects of abiraterone acetate (Zytiga) and low-dose prednisone on prostate-specific antigen and radiographic disease progression in patients with nonmetastatic castration-resistant prostate cancer